Prostemics Co. Ltd
Ark Solutions Inc. engages in the research and development of products using protein in South Korea, Japan, Mexico, and internationally. It operates through Life and Health Business and Exosome Business divisions. The company offers products using stem cells. The company also provides cosmetics for hospitals and clinics, such as AAPE, a products containing high concentration human cell culture me… Read more
Market Cap & Net Worth: Prostemics Co. Ltd (203690)
Prostemics Co. Ltd (KQ:203690) has a market capitalization of $44.14 Million (₩64.64 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #23020 globally and #1214 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prostemics Co. Ltd's stock price ₩4425.00 by its total outstanding shares 14607100 (14.61 Million).
Prostemics Co. Ltd Market Cap History: 2015 to 2025
Prostemics Co. Ltd's market capitalization history from 2015 to 2025. Data shows change from $211.00 Million to $44.14 Million (-18.16% CAGR).
Index Memberships
Prostemics Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.02% | #588 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.02% | #588 of 1384 |
Weight: Prostemics Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prostemics Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prostemics Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Prostemics Co. Ltd's market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $211.00 Million | $14.83 Billion | -$8.52 Billion | 0.01x | N/A |
| 2016 | $210.25 Million | $14.16 Billion | $4.31 Billion | 0.01x | 0.05x |
| 2017 | $356.65 Million | $6.56 Billion | -$3.16 Billion | 0.05x | N/A |
| 2018 | $270.35 Million | $4.72 Billion | -$6.30 Billion | 0.06x | N/A |
| 2019 | $174.08 Million | $7.13 Billion | -$3.18 Billion | 0.02x | N/A |
| 2020 | $219.48 Million | $20.73 Billion | -$7.27 Billion | 0.01x | N/A |
| 2021 | $137.42 Million | $32.53 Billion | -$7.24 Billion | 0.00x | N/A |
| 2022 | $49.28 Million | $26.58 Billion | -$5.56 Billion | 0.00x | N/A |
| 2023 | $101.36 Million | $37.25 Billion | -$24.37 Billion | 0.00x | N/A |
Competitor Companies of 203690 by Market Capitalization
Companies near Prostemics Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Prostemics Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Prostemics Co. Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Prostemics Co. Ltd's market cap moved from $211.00 Million to $ 44.14 Million, with a yearly change of -18.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩44.14 Million | -20.98% |
| 2024 | ₩55.87 Million | -44.88% |
| 2023 | ₩101.36 Million | +105.67% |
| 2022 | ₩49.28 Million | -64.14% |
| 2021 | ₩137.42 Million | -37.39% |
| 2020 | ₩219.48 Million | +26.07% |
| 2019 | ₩174.08 Million | -35.61% |
| 2018 | ₩270.35 Million | -24.20% |
| 2017 | ₩356.65 Million | +69.63% |
| 2016 | ₩210.25 Million | -0.35% |
| 2015 | ₩211.00 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 21st, 2026 the market cap of Prostemics Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.14 Million USD |
| MoneyControl | $44.14 Million USD |
| MarketWatch | $44.14 Million USD |
| marketcap.company | $44.14 Million USD |
| Reuters | $44.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.